Apr. 4, 2025 — A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody ... and open up opportunities ...

"This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic ... Existing investors ...

NICE has approved Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) for diffuse large B-cell lymphoma (DLBCL) in adults who did not respond to two or more previous treatments. The drug will be ...

Researchers at Memorial Sloan Kettering Cancer Center (MSK) have announced progress on that front — they have developed a new therapy that uses stem cells to ... "This is a small study designed ...

Background Fibrolamellar carcinoma (FLC), a rare and fatal liver cancer lacking effective drug therapy, is driven by the DNAJ ...

The treatment will be available in the third line setting for all adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma ...

Patients suffering from Parkinson's disease may soon benefit from a powerful treatment option: stem-cell transplants. In a pair of small studies designed primarily to test safety, two teams of ...

They explore how metabolic shifts drive lymphoma progression, the potential of immunotherapy, and what the future holds for treating lymphoid malignancies. John Riches is a Clinical Reader in Cancer ...